Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

24 settimane in doppio cieco randomizzato controllato con placebo per valutare l'efficacia, PK, la sicurezza di LOU064 negli adolescenti (12 -

14 ottobre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio in doppio cieco, randomizzato, controllato con placebo per valutare l'efficacia, la farmacocinetica e la sicurezza di Remibrutinib (LOU064) per 24 settimane in adolescenti di età compresa tra 12 e meno di 18 anni con orticaria cronica spontanea non adeguatamente controllata da antistaminici H1 seguiti da un'estensione opzionale in aperto per un massimo di altri 3 anni e un periodo di follow-up opzionale di sicurezza a lungo termine senza trattamento per un massimo di altri 3 anni

The purpose of this trial is:

  1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to < 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines
  2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment
  3. to collect safety data in this population for up to three years after the last dose of study treatment

Panoramica dello studio

Stato

Attivo, non reclutante

Descrizione dettagliata

This trial consists of 3 different periods:

  1. the "core period", which is randomized and double-blind, during which 2/3 participants will receive remibrutinib and 1/3 will receive placebo for 24 weeks. Total duration: approximately 32 weeks (10 site visits).
  2. an optional "open-label extension (OLE) period" proposed to all participants who completed 24 weeks of treatment of the "core period" and all scheduled assessments planned at week 24 visit . Depending on their CSU symptoms (as assessed by the doctor), participants will either receive remibrutinib for 24 weeks, or enter an observational treatment-free period for 1 year. If the CSU symptoms return during the observational period, the participants can switch to the treatment period at any time (decided by the doctor). At the end of the 24-week treatment period, if CSU is controlled, participants will enter the 1-year observational period, otherwise, they can continue with another cycle of 24-week remibrutinib treatment. The number of remibrutinib treatment or observational cycles will be limited to 6 times each. Total duration: from 1 year to approximately 3 years, and number of visits: from 3 to 15 (depending on the CSU symptoms).
  3. an optional "long-term treatment-free follow-up period" proposed to all participants who completed at least 4 months treatment in the "OLE period". No treatment will be given. Duration: 3 years with 1 site visit and up to 4 phone call follow-up visits.

The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment

Tipo di studio

Interventistico

Iscrizione (Effettivo)

100

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • CABA, Argentina, C1181ACH
        • Novartis Investigative Site
      • San Miguel de Tucumán, Argentina, T4000AXL
        • Novartis Investigative Site
    • Buenos Aires
      • CABA, Buenos Aires, Argentina, C1414AIF
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentina, S2000DEJ
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Novartis Investigative Site
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 8420383
        • Novartis Investigative Site
      • Beijing, Cina, 100050
        • Novartis Investigative Site
      • Beijing, Cina, 100069
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510091
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • Novartis Investigative Site
      • Berlin, Germania, 13353
        • Novartis Investigative Site
      • Tübingen, Germania, 72076
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Germania, 60590
        • Novartis Investigative Site
    • Fukuoka
      • Kitakyushu, Fukuoka, Giappone, 8078556
        • Novartis Investigative Site
    • Kumamoto
      • Kamimashi-gun, Kumamoto, Giappone, 8613106
        • Novartis Investigative Site
    • Osaka
      • Sakai, Osaka, Giappone, 5938324
        • Novartis Investigative Site
    • Shimane
      • Izumo, Shimane, Giappone, 6938501
        • Novartis Investigative Site
    • Tokyo
      • tabashi City, Tokyo, Giappone, 1738610
        • Novartis Investigative Site
    • Hong Kong
      • Hong Kong, Hong Kong, Hong Kong, 999077
        • Novartis Investigative Site
    • FI
      • Florence, FI, Italia, 50139
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Italia, 27100
        • Novartis Investigative Site
    • SI
      • Siena, SI, Italia, 53100
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malaysia, 93586
        • Novartis Investigative Site
      • Utrecht, Olanda, 3584 CX
        • Novartis Investigative Site
      • Lodz, Polonia, 90-436
        • Novartis Investigative Site
      • Manchester, Regno Unito, M13 9WL
        • Novartis Investigative Site
      • Southampton, Regno Unito, SO16 6YD
        • Novartis Investigative Site
    • Cambridgeshire
      • Peterborough, Cambridgeshire, Regno Unito, PE3 9GZ
        • Novartis Investigative Site
      • Valencia, Spagna, 46014
        • Novartis Investigative Site
    • Barcelona
      • Esplugues, Barcelona, Spagna, 08950
        • Novartis Investigative Site
    • California
      • Bakersfield, California, Stati Uniti, 93301
        • Kern Research
      • San Diego, California, Stati Uniti, 92123
        • Allergy and Asthma Medical Group and Research Center
    • Florida
      • Miami, Florida, Stati Uniti, 33156
        • Pediatric Dermatology of Miami at the Pediatric CoE
    • Idaho
      • Boise, Idaho, Stati Uniti, 83706
        • Treasure Valley Medical Research
    • Illinois
      • Glenview, Illinois, Stati Uniti, 60077
        • Endeavor Health
    • Kentucky
      • Owensboro, Kentucky, Stati Uniti, 42301
        • Allergy and Asthma Specialist P S C
    • Ohio
      • Toledo, Ohio, Stati Uniti, 43617
        • Toledo Institute of Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73120
        • Allergy Asthma and Clinical Research
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15241
        • Allergy and Clinical Immunology Associates
    • Texas
      • San Antonio, Texas, Stati Uniti, 78213
        • RFSA Dermatology
    • Utah
      • Sandy City, Utah, Stati Uniti, 84093
        • Allergy Associates of Utah
      • Cape Town, Sud Africa, 7925
        • Novartis Investigative Site
    • Gauteng
      • Pretoria, Gauteng, Sud Africa, 0181
        • Novartis Investigative Site
      • Bangkok, Tailandia, 10330
        • Novartis Investigative Site
      • Bangkok, Tailandia, 10700
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Tailandia, 90110
        • Novartis Investigative Site
      • Adana, Turchia (Türkiye), 01330
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turchia (Türkiye), 34093
        • Novartis Investigative Site
    • Sihhiye Altindag
      • Ankara, Sihhiye Altindag, Turchia (Türkiye), 06230
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 12 anni a 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  • Male and female adolescent participants aged >= 12 to < 18 years of age at the time of signing the informed consent
  • CSU duration for >= 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation)
  • Diagnosis of CSU inadequately controlled by second-generation H1-AH at the time of randomization defined as:
  • The presence of itch and hives for ≥ 6 consecutive weeks prior to screening despite the use of second-generation H1-AH during this time period according to local treatment guidelines
  • UAS7 score (range 0 - 42) >= 16, ISS7 score (range 0 - 21) >= 6 and HSS7 score (range 0 - 21) >= 6 during the 7 days prior to randomization (Day 1)
  • Documentation of hives within three months before randomization (either at screening and/or at randomization; or documented in the participants' medical history)

Key Exclusion criteria:

  • Previous use of remibrutinib or other BTK inhibitors
  • Significant bleeding risk or coagulation disorders
  • History of gastrointestinal bleeding
  • Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited
  • History or current hepatic disease
  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant
  • History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes
  • Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria
  • Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria
  • Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis

Other protocol-defined inclusion/exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1: LOU064 (blinded)

LOU064 (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally b.i.d. for up to 6 cycles of 24 weeks.

LOU064 (blinded) active treatment

Altri nomi:
  • remibrutinib
Comparatore placebo: Arm 2: LOU064 placebo (blinded)

LOU064 placebo (blinded) taken orally b.i.d. for 24 weeks (randomized in a 2:1 ratio arm 1: arm 2)

matching active drug

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change from baseline in UAS7
Lasso di tempo: Baseline, week 12

The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42. Complete UAS7 response is UAS7 = 0.

Negative change from baseline indicates improvement.

Baseline, week 12
Change fron baseline in ISS7
Lasso di tempo: Baseline, Week 12

Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).

Negative change from baseline indicates improvement.

Baseline, Week 12
Change from baseline in HSS7
Lasso di tempo: Baseline, Week 12

Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours).

Negative change from baseline indicates improvement.

Baseline, Week 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cmax of remibrutinib
Lasso di tempo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The maximum (peak) observed blood drug concentration after single dose administration

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
Tmax of remibrutinib
Lasso di tempo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The time to reach maximum (peak) blood drug concentration after single dose administration

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
AUClast of remibrutinib
Lasso di tempo: At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake

The Area Under the Curve (AUC) from pre-dose to the last measurable concentration sampling time

At Week 12, before study drug intake, then after 30 min, 1 h, 2h, 3h and 4 h after study drug intake
Absolute change from baseline in ISS7
Lasso di tempo: Baseline - Week 12

Itch Severity Score (ISS) scale is 0 to 3. Score (ISS7) is derived by adding up average daily scores of 7 days preceding visit. Possible range of weekly score is therefore 0 to 21. Itch Severity Score scale: 0 - None 1 - Mild (minimal awareness, easily tolerated) 2 - Moderate (definite awareness, bothersome but tolerable) 3 - Severe (difficult to tolerate).

Negative change from baseline indicates improvement.

Baseline - Week 12
Absolute change from baseline in HSS7
Lasso di tempo: Baseline - Week 12

Hives Severity Score (HSS) scale is 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. Possible range of the weekly score is therefore 0 to 21. Hives Severity Score scale: 0 - None 1 - Mild (1-6 hives/12 hours) 2 - Moderate (7-12 hives/12 hours) 3 - Severe (>12 hives/12 hours).

Negative change from baseline indicates improvement.

Baseline - Week 12
Achievement of UAS7 ≤ 6 (yes/no)
Lasso di tempo: Week 12 and over time

Disease activity control is defined as UAS7 ≤ 6. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

Week 12 and over time
Achievement of UAS7 = 0 (yes/no)
Lasso di tempo: Week 12 and over time

Complete absence of hives and itch is defined as UAS7 = 0. The Urticaria Activity Score (UAS) is sum of the Hive Severity Score (HSS) and the Itch Severity Score (ISS). UAS7 is sum of the HSS7 and the ISS7 scores. Possible range of weekly UAS7 score is 0 to 42.

Week 12 and over time
Absolute change from baseline in CDLQI score
Lasso di tempo: Week 12

The Children Dermatology life Quality Index (CDLQI) score range is 0 to 30, with 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).

Week 12
Number of weeks without angioedema, assessed by the cumulative number of weeks with an AAS7 = 0 response
Lasso di tempo: baseline - Week 12

Angioedema Activity Score (AAS7) is a measure of the frequency and intensity of angioedema episodes. The total possible range of scores over 7 days is 0-105 where higher scores indicate increased angioedema activity.

baseline - Week 12
Occurrence of treatment-emergent adverse events (AE) and serious adverse events (SAE) during the core period
Lasso di tempo: 28 weeks

To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the core period of the study.

28 weeks
Occurrence of treatment emergent AEs, and SAEs during the Open Label Extension (OLE) period
Lasso di tempo: 3 years

To demonstrate the safety and tolerability of remibrutinib by assessing occurrence of treatment emergent adverse events and serious adverse events during the OLE period of the study.

3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 luglio 2023

Completamento primario (Stimato)

3 novembre 2026

Completamento dello studio (Stimato)

30 marzo 2032

Date di iscrizione allo studio

Primo inviato

16 dicembre 2022

Primo inviato che soddisfa i criteri di controllo qualità

23 dicembre 2022

Primo Inserito (Effettivo)

10 gennaio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi